Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Should You Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares gapped up prior to trading on Monday . The stock had previously closed at $15.90, but opened at $18.00. Structure Therapeutics shares last traded at $17.69, with a volume of 145,502 shares.

Analysts Set New Price Targets

A number of research firms have weighed in on GPCR. Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Down 0.3 %

The firm has a market capitalization of $1.08 billion, a P/E ratio of -25.54 and a beta of -1.35. The company has a fifty day simple moving average of $20.52 and a 200 day simple moving average of $28.88.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors have recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd lifted its position in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Structure Therapeutics during the fourth quarter valued at $34,000. FNY Investment Advisers LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter valued at $40,000. Finally, Virtus ETF Advisers LLC increased its holdings in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after buying an additional 455 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.